0001104659-23-038409.txt : 20230329 0001104659-23-038409.hdr.sgml : 20230329 20230329170932 ACCESSION NUMBER: 0001104659-23-038409 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230323 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230329 DATE AS OF CHANGE: 20230329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gardiner Healthcare Acquisitions Corp. CENTRAL INDEX KEY: 0001858912 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 862899992 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41185 FILM NUMBER: 23776100 BUSINESS ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 BUSINESS PHONE: 216-633-6708 MAIL ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 8-K 1 tm2310865d1_8k.htm FORM 8-K
0001858912 false 0001858912 2023-03-23 2023-03-23 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-03-23 2023-03-23 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-03-23 2023-03-23 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-03-23 2023-03-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(D) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 29, 2023 (March 23, 2023)

 

GARDINER HEALTHCARE ACQUISITIONS CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-41185   86-2899992
(State or other jurisdiction of
incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

3107 Warrington Road
Shaker Heights, Ohio
  44120
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (216) 633-6708

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on 
which registered
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant   GDNRU   The Nasdaq Stock Market LLC
Shares of common stock, par value $0.0001 per share, included as part of the units   GDNR   The Nasdaq Stock Market LLC
Redeemable warrants included as part of the units   GDNRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On March 23, 2023 and March 24, 2023, Gardiner Healthcare Acquisitions Corp. (the “Company”) issued two unsecured promissory notes (each, a “Convertible Note” and, collectively, the “Convertible Notes”) to Payees (as defined below), pursuant to which the Company is entitled to borrow an aggregate of up to $549,359.35 for costs, fees and expenses related to the Company’s operations, including those relating to the preparation, negotiation and consummation of an intended Business Combination (as defined below). All unpaid principal under the Convertible Notes will be due and payable in full on the earlier of (i) June 27, 2023 (the “Maturity Date”) and (ii) the date on which the Company consummates an initial business combination (the “Business Combination”).

 

The Convertible Note entered into by the Company on March 23, 2023 was issued to Moss Ridge PTY LTD (“Moss Ridge”) for a principal sum of up to $534,723.35 and the Convertible Note entered into by the Company on March 24, 2023 was issued to Anthony Julien (“Julien” and, together with Moss Ridge, each a “Payee” and, collectively, the “Payees”) for a principal sum of up to $14,636.

 

Pursuant to the terms of the Convertible Notes, each Payee will have the option, at any time on or prior to the Maturity Date, to convert any amounts outstanding under the Convertible Notes into warrants to purchase the Company’s shares of common stock, par value $0.0001 per share (“Common Stock”), at a conversion price of $1.00 per warrant, with each warrant entitling the holder to purchase one share Common Stock at a price of $11.50 per share, subject to the same adjustments applicable to the private placement warrants sold concurrently with the Company’s initial public offering.

 

A copy of the form of Convertible Note is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing description of the Convertible Note is qualified in its entirety by reference thereto.

 

On March 24, 2023, the Company also issued an unsecured promissory note (the “Promissory Note”) to Gardiner Warrant Holdings LLC, an affiliate of the Company, pursuant to which the Company is entitled to borrow an aggregate of up to $14,190.00 for costs, fees and expenses related to the Company’s operations, including those relating to the preparation, negotiation and consummation of an intended Business Combination. All unpaid principal under the Promissory Note will be due and payable in full on the earlier of (i) the Maturity Date and (ii) the date on which the Company consummates a Business Combination.

 

A copy of the Promissory Note is filed with this Current Report on Form 8-K as Exhibit 10.2 and is incorporated herein by reference, and the foregoing description of the Promissory Note is qualified in its entirety by reference thereto.

 

Sponsor Support Agreement

 

In connection with entering into the Convertible Note, on February 6, 2023, the Payees, Gardiner Healthcare Holdings, LLC, a Delaware limited liability company (“Gardiner Sponsor”), Chardan Gardiner LLC, a Delaware limited liability company (“Chardan Sponsor”), and CCMAUS Pty Ltd., an Australian company (together with the Gardiner Sponsor and Chardan Sponsor, the “Sponsors” and each, a “Sponsor” of the Company) entered into a Sponsor Support Agreement (the “Sponsor Support Agreement”), pursuant to which, among other things, the Sponsors agreed to assign and transfer to the Lenders a certain number of shares of Common Stock owned by the Sponsors in accordance with the terms of such Sponsor Support Agreement, as an inducement for the Lenders to make the Loans.

 

A copy of the Sponsor Support Agreement is filed with this Current Report on Form 8-K as Exhibit 10.3 and is incorporated herein by reference, and the foregoing description of the Sponsor Support Agreement is qualified in its entirety by reference thereto.

 

  

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

 

 

 

The information set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein. The issuance of each of the Convertible Notes, including any issuance of private placement warrants thereunder, was made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit   Description
10.1   Form of Convertible Note.
10.2   Promissory Note, dated as of March 24, 2023.
10.3   Sponsor Support Agreement, dated as of March 24, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Gardiner Healthcare Acquisitions Corp.
     
Date: March 29, 2023 By: /s/ Marc F. Pelletier
    Name: Marc F. Pelletier
    Title: Chief Executive Officer

 

 

 

EX-10.1 2 tm2310865d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

THE OFFER AND SALE OF THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: [_____]

Dated as of March [__], 2023

Shaker Heights, Ohio

 

Gardiner Healthcare Acquisitions Corp., a Delaware corporation and blank check company (the “Maker”), promises to pay to the order of [____________________________] or its registered assigns or successors in interest (together, the “Payee”), the principal sum of up to [________________] (the “Maximum Amount”) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds, or as otherwise determined by Maker, to such account as Payee may from time to time designate by Notice (as defined in Section 9) to Maker in accordance with the provisions of this Note.

 

1. Principal. The principal balance of this Note shall be payable by Maker on the earlier of: (i) June 27, 2023 (the “Maturity Date”) or (ii) the date on which the Maker consummates an initial business combination (the “Business Combination”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of Maker, be obligated personally for any obligations or liabilities of Maker hereunder.

 

2. Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3. Drawdown Requests. Maker and Payee agree that Maker may request from the Payee or its affiliates up to the Maximum Amount for costs reasonably related to Maker’s operations, including consummation of the Business Combination. The principal of this Note may be drawn down from time to time prior to the earlier of: (i) June 27, 2023; or (ii) the date on which Maker consummates an initial business combination, upon written request from Maker to Payee (each, a “Drawdown Request”). Each Drawdown Request must state the amount to be drawn down, and must not be an amount less than Ten Thousand Dollars ($10,000), unless agreed upon by Maker and Payee. Payee shall fund each Drawdown Request no later than five business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns collectively under this Note shall not exceed the Maximum Amount. Once an amount is drawn down under this Note, such amount shall not be available for future Drawdown Requests, even if such amount is prepaid. No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Maker. Notwithstanding the foregoing, all payments shall be applied, first, to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorneys’ fees, and second, to the reduction of the unpaid principal balance of this Note.

4. Application of Payments. All payments shall be applied, first, to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, second, to the payment in full of any late charges, and third, to the reduction of the unpaid principal balance of this Note.

 

5. Conversion. At the date of the Business Combination or upon the Maker’s discretion, the Payee shall have the option, but not the obligation, to convert the principal balance of this Note, in whole or in part at the option of the Payee, into warrants (“Warrants”) of the Maker at a price of $1.00 per Warrant, each Warrant being identical to the “private warrant” (as defined in Maker’s prospectus dated December 21, 2021). As promptly after notice by Payee to Maker to convert the principal balance of this Note, which must be made at least 24 hours prior to the consummation of the Business Combination, as reasonably practicable and after Payee’s surrender of this Note, Maker shall have issued and delivered to Payee, without any charge to Payee, in book-entry form or a certificate or certificates (issued in the name(s) requested by Payee) for the number of Warrants of Maker issuable upon the conversion of this Note.

 

 

 

 

6. Events of Default. The following events shall constitute an event of default (“Event of Default”):

 

6.1 Failure to Make Required Payments. The failure by Maker to pay the principal amount due pursuant to this Note within five business days of the Maturity Date.

 

6.2 Voluntary Bankruptcy, Etc. The: (a) commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law; (b) consent by Maker to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker for any substantial part of its property, (c) making by Maker of any assignment for the benefit of creditors; (d) the failure of Maker generally to pay its debts as such debts become due; or (e) taking of any corporate action by Maker in furtherance of any of the foregoing events described in Section 6.2(a)Section 6.2(d).

 

6.3 Involuntary Bankruptcy, Etc. The: (a)(i) entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, (ii) appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or (iii) the ordering of the winding-up or liquidation of Maker’s affairs; and (b) continuance of any such decree, appointment, or order unstayed and in effect for a period of 60 consecutive days.

 

7. Remedies.

 

7.1 Upon the occurrence of an Event of Default specified in Section 6.1, Payee may, by Notice to Maker, declare this Note to be due immediately and payable by Maker, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in the documents evidencing the same to the contrary.

 

7.2 Upon the occurrence of an Event of Default specified in Section 6.2 and Section 6.3, the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable by Maker, in all cases without any action on the part of Payee.

 

8. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive: (a) presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note; (b) all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note; and (c) all benefits that might accrue to Maker by virtue of any present or future laws (i) exempting any property, real or personal, or any part of the proceeds arising from any sale of any such real or personal property, from attachment, levy or sale under execution, or (ii) providing for any stay of execution, exemption from civil process, or extension of time for payment. Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that Maker’s liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee. Maker consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note. Maker agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without either any Notice to Maker or any bearing on Maker’s liability hereunder.

 

10. Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a “Notice”) shall be in writing and addressed to the parties at the addresses set forth on the first page of this Agreement (or to such other address that may be designated by the receiving party from time to time in accordance with this Section 10). A Notice shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or email (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail (in each case, return receipt requested, postage pre-paid).

 

 

 

 

11. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13. Trust Waiver. Notwithstanding anything herein to the contrary, Payee hereby waives any and all right, title, interest or claim of any kind (each, a “Claim”) in or to any distribution of or from the trust account (the “Trust Account”), in which the proceeds of both the (a) initial public offering of the Maker (the “IPO”) (including the deferred underwriters discounts and commissions) and (b) sale of the warrants issued in a private placement to occur at the closing of the IPO were deposited, as described in greater detail in the Registration Statement on Form S-1 and prospectus filed with the Securities and Exchange Commission in connection with the IPO. Payee hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

14. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of both Maker and Payee.

 

15. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto. Any attempted assignment without the required consent shall be void.

 

[Signature page follows]

 

 

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

 

Gardiner Healthcare Acquisitions Corp.

   
  By:  
    Name: Marc F. Pelletier
    Title: Chairman and Chief Executive Officer

 

[Signature Page to Promissory Note]

 

 

 

EX-10.2 3 tm2310865d1_ex10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

THE OFFER AND SALE OF THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: U.S. $14,190.00

Dated as of March 24, 2023

Shaker Heights, Ohio

 

Gardiner Healthcare Acquisitions Corp., a Delaware corporation and blank check company (the “Maker”), promises to pay to the order of Gardiner Warrant Holdings LLC or its registered assigns or successors in interest (together, the “Payee”), the principal sum of up to Fourteen Thousand, One Hundred Ninety and 00/100 U.S. Dollars in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds to such account as Payee may from time to time designate by Notice (as defined in Section 9) to Maker in accordance with the provisions of this Note.

 

1. Principal. The principal balance of this Note shall be payable by Maker on the earlier of: (i) June 27, 2023 (the “Maturity Date”) or (ii) the date on which the Maker consummates an initial business combination (the “Business Combination”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of Maker, be obligated personally for any obligations or liabilities of Maker hereunder.

 

2. Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3. [Intentionally Omitted.]

 

4. Application of Payments. All payments shall be applied, first, to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, second, to the payment in full of any late charges, and third, to the reduction of the unpaid principal balance of this Note.

 

5. [Intentionally Omitted.]

 

6. Events of Default. The following events shall constitute an event of default (“Event of Default”):

 

6.1 Failure to Make Required Payments. The failure by Maker to pay the principal amount due pursuant to this Note within five business days of the Maturity Date.

 

6.2 Voluntary Bankruptcy, Etc. The: (a) commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law; (b) consent by Maker to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker for any substantial part of its property, (c) making by Maker of any assignment for the benefit of creditors; (d) the failure of Maker generally to pay its debts as such debts become due; or (e) taking of any corporate action by Maker in furtherance of any of the foregoing events described in Section 6.2(a)Section 6.2(d).

 

6.3 Involuntary Bankruptcy, Etc. The: (a)(i) entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, (ii) appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or (iii) the ordering of the winding-up or liquidation of Maker’s affairs; and (b) continuance of any such decree, appointment, or order unstayed and in effect for a period of 60 consecutive days.

 

 

 

 

7. Remedies.

 

7.1 Upon the occurrence of an Event of Default specified in Section 6.1, Payee may, by Notice to Maker, declare this Note to be due immediately and payable by Maker, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in the documents evidencing the same to the contrary.

 

7.2 Upon the occurrence of an Event of Default specified in Section 6.2 and Section 6.3, the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable by Maker, in all cases without any action on the part of Payee.

 

8. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive: (a) presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note; (b) all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note; and (c) all benefits that might accrue to Maker by virtue of any present or future laws (i) exempting any property, real or personal, or any part of the proceeds arising from any sale of any such real or personal property, from attachment, levy or sale under execution, or (ii) providing for any stay of execution, exemption from civil process, or extension of time for payment. Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that Maker’s liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee. Maker consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note. Maker agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without either any Notice to Maker or any bearing on Maker’s liability hereunder.

 

10. Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a “Notice”) shall be in writing and addressed to the parties at the addresses set forth on the first page of this Agreement (or to such other address that may be designated by the receiving party from time to time in accordance with this Section 10). A Notice shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or email (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail (in each case, return receipt requested, postage pre-paid).

 

11. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13. Trust Waiver. Notwithstanding anything herein to the contrary, Payee hereby waives any and all right, title, interest or claim of any kind (each, a “Claim”) in or to any distribution of or from the trust account (the “Trust Account”), in which the proceeds of both the (a) initial public offering of the Maker (the “IPO”) (including the deferred underwriters discounts and commissions) and (b) sale of the warrants issued in a private placement to occur at the closing of the IPO were deposited, as described in greater detail in the Registration Statement on Form S-1 and prospectus filed with the Securities and Exchange Commission in connection with the IPO. Payee hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

- 2 -

 

 

14. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of both Maker and Payee.

 

15. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto. Any attempted assignment without the required consent shall be void.

 

[Signature page follows]

 

- 3 -

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

  Gardiner Healthcare Acquisitions Corp.
   
  By: /s/ Marc F. Pelletier
    Name: Marc F. Pelletier
    Title: Chairman and Chief Executive Officer

 

[Signature Page to Promissory Note]

 

 

 

EX-10.3 4 tm2310865d1_ex10-3.htm EXHIBIT 10.3

 

Exhibit 10.3

 

SPONSOR SUPPORT AGREEMENT

 

This Sponsor Support Agreement (this “Sponsor Agreement”) is dated as of February 6, 2023 by and among Gardiner Healthcare Holdings, LLC, a Delaware limited liability company (“Gardiner Sponsor”), Chardan Gardiner LLC, a Delaware limited liability company (“Chardan Sponsor”), and CCMAUS Pty Ltd., an Australian company (“CCMAUS” and together with the Gardiner Sponsor and Chardan Sponsor, each, a “Sponsor” and, together, the “Sponsors”), one the one-hand, and each of the persons set forth on Schedule I hereto (each, a “Lender” and, together, the “Lenders”), on the other hand.

 

RECITALS

 

WHEREAS, as of the date hereof, the Sponsors are the holders of record and the “beneficial owners” (within the meaning of Rule 13d-3 under the Exchange Act) of such number of shares of the common stock (the “Common Stock”) of Gardiner Healthcare Acquisitions Corp., a Delaware corporation (the “Company”), as are indicated opposite each of their names on Schedule I attached hereto;

 

WHEREAS, the registration statement on Form S-1 in relation to the Company’s initial public offering provides that in order to meet the Company’s working capital needs, its initial stockholders, officers and directors and their respective affiliates may, but are not obligated to, loan the Company funds, from time to time, pursuant to a promissory note to be paid upon consummation of the Company’s initial business combination (“Business Combination”), without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted upon consummation of the Company’s business combination into additional private warrants to purchase shares of common stock at a conversion price of $1.00 per private warrant;

 

WHEREAS, contemporaneously with the execution and delivery of this Sponsor Agreement each of the Lenders has entered into a convertible promissory note, dated as of the date hereof, substantially in the form attached hereto as Exhibit A (each, a “Promissory Note”) pursuant to which, the Lenders have agreed to loan to the Company up to the respective amounts set forth on Schedule [I], which aggregate the total potential loan amount of [One Million Five Hundred Thousand Dollars ($1,500,000)] (each, a “Loan” and, collectively, the “Loans”); and

 

WHEREAS, as an inducement to the Lenders to make the Loans, the parties hereto desire to agree to certain matters as set forth herein.

 

 

 

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

Article I

SPONSOR SUPPORT AGREEMENT; COVENANTS

 

Section 1.1. Binding Effect. Each Sponsor and Lender hereby acknowledges that it has read this Agreement, the Promissory Note and has had the opportunity to consult with its tax and legal advisors. Each Lender shall be bound by the Promissory Note and make the Loans contemplated thereby to the extent so requested by the Company.

 

Section 1.2. Transfer Restrictions.

 

(a)               Each of the Sponsors and the Lenders acknowledges and agrees that the Sponsors are subject to the terms and conditions of (i) the Stock Escrow Agreement, dated as of December 21, 2021, by and between the Company and each of the initial stockholders thereto, including (amongst others) each of the Sponsors (the “Escrow Agreement”), and (ii) a Letter Agreement, dated December 21, 2021, by and among the Company and each of the Sponsors (the “Insider Letter Agreement”) and that each of the Escrow Agreement and the Insider Letter Agreement contains limitations on transfer. The parties hereto represent, warrant and covenants that each of the Lenders is a permitted transferee in accordance with Section 4.3 of the Escrow Agreement and Section 5 of the Insider Letter Agreement. Each of the Lenders represents and warrants that it is not subject to any further limitations on transfer, except those set forth in the Escrow Agreement, the Insider Letter Agreement and applicable law.

 

(b)               During the period commencing on the date hereof and ending on the expiration or termination of the Promissory Note (the “Expiration Time”), each Sponsor shall not (x) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, file (or participate in the filing of) a registration statement with the SEC (other than (i) participation in the preparation of a proxy statement or registration statement relating to the Company’s initial business combination, and/or (ii) participation in the preparation of a registration statement and/or sponsor support agreement relating to a private investment in public equity offering in conjunction with the Company’s initial business combination (the “PIPE”)) or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, with respect to any shares of Common Stock owned by such Sponsor, in each case that would be effective prior to the Expiration Time, (y) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of Common Stock owned by such Sponsor, in each case that would be effective prior to the Expiration Time (clauses (x) and (y) collectively, a “Transfer”) or (z) publicly announce any intention to effect any transaction specified in clause (x) or (y); provided, however, that the foregoing shall not prohibit Transfers to the extent permitted under the Escrow Agreement, so long as, prior to and as a condition to the effectiveness of any such Transfer, any transferee executes and delivers a joinder to this Support Agreement in the form attached hereto as Annex A (in addition to such transfer requirements as set forth in the Escrow Agreement).

 

(c)               The parties acknowledge that any shares transferred hereunder shall be legended in substantially the following form to reflect that such shares are subject to restrictions pursuant to this Sponsor Agreement:

 

“THE SECURITIES EVIDENCED HEREIN ARE SUBJECT TO RESTRICTIONS ON TRANSFER, AND CERTAIN OTHER AGREEMENTS, SET FORTH IN THE SPONSOR SUPPORT AGREEMENT, DATED AS OF FEBRUARY 6, 2023, BY AND AMONG Gardiner Healthcare Holdings, LLC, Chardan Gardiner LLC, and CCMAUS Pty Ltd. and each of the persons set forth on Schedule I Thereto.

 

 

 

 

Section 1.3. Additional Sponsor Agreement re: Transfer of Shares.

 

(a)        Subject to the terms and conditions of this Agreement, in conjunction with, and subject to, the closing of the Business Combination, the Sponsors hereby agree to collectively assign and transfer to each Lender a number of shares of Common Stock owned by the Sponsors (the “Sponsor Common Stock”) equal to 4.992 shares of Sponsor Common Stock for each One Hundred Dollars in principal loaned by such Lender pursuant to its applicable Promissory Note; provided, however, such number of shares of Sponsor Common Stock shall be rounded down to the next whole number of shares. In furtherance of the foregoing, no fractional shares of Sponsor Common Stock shall be transferred hereunder.

 

For example, a person that lends the Company One Hundred Thousand dollars ($100,000) pursuant to a Promissory Note shall be entitled to receive Nine Thousand Nine Hundred Eighty Four (9,984) shares of Sponsor Common Stock upon closing of the Business Combination, as follows:

 

X = ($100,000/$100) x 9.984,

 

Where X is the number of shares of Sponsor Common Stock to be received.

 

(b)        Each of the Lenders hereby expressly acknowledges that the Company is currently in discussions with a potential Business Combination target and that the discussions (which are not binding) currently contemplate that a portion of the Sponsor Common Stock held by each Sponsor (currently proposed to be up to 25%) shall be subject to forfeiture in the event that the Company (or its successor) does not meet certain performance milestones following the closing of the Business Combination. Each of the Lenders further acknowledges that the terms and conditions associated with the Sponsor Common Stock, including without limitation forfeitures, lock-ups, other restrictions, limitations and/or conditions, are subject to negotiations between and among the Company, business combination target entities and affiliates, and the Sponsors, and may change from the proposal described in the foregoing sentence. In furtherance of the foregoing, each Lender hereby agrees that all shares of Sponsor Common Stock received by the Lender in accordance with this Agreement shall be subject to all restrictions, limitations and/or conditions currently in effect and hereafter agreed upon by the Sponsors; provided, however, all such restrictions, limitations and/or conditions that apply to the shares of Sponsor Common Stock assigned to the Lenders hereunder shall be pari passu with the restrictions, limitations and/or conditions retained by the Sponsors. Each Lender acknowledges and agrees that it shall have no rights to vote the Sponsor Common Stock until conveyed in accordance with this Agreement. Furthermore, each Lender acknowledges and agrees that it shall have no rights whatsoever to negotiate the terms and conditions of the Business Combination and shall have no rights to negotiate the terms and conditions, including restrictions, limitations and/or conditions, pertaining to the Sponsor Common Stock.

 

 

 

 

(c)       On or about the closing of the Business Combination, the Sponsors shall execute appropriate transfer documentation with each Lender providing for the transfer to such Lender of the applicable number of shares of Sponsor Common Stock.

 

(c)       The Sponsors agree that, as between the Sponsors, the total numbers of shares of Sponsor Common Stock transferred to all of the Lenders, collectively, in accordance with this Agreement shall be allocated as follows: 78.5% Gardiner Sponsor, 10.8% Chardan Sponsor and 10.3% CCMAUS. The Sponsors and the Lenders acknowledge and agree that such allocation shall not necessarily apply to the transfer of Sponsor Common Stock to any given Lender (i.e., a Lender may receive its allocation of Sponsor Common Stock from 1, 2 or all 3 of the Sponsors, as determined by the Sponsors at their discretion).

 

Section 1.4. New Shares. In the event that any shares of Common Stock or other equity securities of Company (or its successor) are issued to a Sponsor after the date of this Sponsor Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification, combination or exchange of shares of Common Stock of, on or affecting the shares of Common Stock owned by such Sponsor or otherwise (such shares of Common Stock or other equity securities, collectively the “New Securities”), then such New Securities acquired by such Sponsor shall be subject to the terms of this Sponsor Agreement to the same extent as if they constituted the shares of Common Stock owned by such Sponsor as of the date hereof.

 

Section 1.5. Joinder to Escrow Agreement. To the extent applicable, each Lender, on behalf of itself, agrees that it will deliver, substantially simultaneously with the Business Combination, with respect to its allocation of Sponsor Common Stock, a duly-executed joinder to the Escrow Agreement (or similar agreement) substantially in the form to be agreed upon by and between the parties to the Escrow Agreement.

 

Section 1.6. Joinder to Insider Letter Agreement. To the extent applicable, each Lender, on behalf of itself, agrees that it will deliver, substantially simultaneously with the closing of the Business Combination, with respect to its allocation of the Sponsor Common Stock, a duly-executed joinder to the Insider Letter Agreement (or similar agreement) substantially in the form to be agreed upon by and between the parties to the Insider Letter Agreement.

 

Section 1.7. Registration Rights Agreement. Each Lender, on behalf of itself, agrees that it will deliver, substantially simultaneously with the closing of the Business Combination, with respect to its allocation of the Sponsor Common Stock, a duly-executed copy of any applicable registration rights agreement(s).

 

 

 

 

Section 1.8. Lock-Up Agreement. Each Lender, on behalf of itself, agrees that it will deliver, substantially simultaneously with the closing of the Business Combination, with respect to its allocation of Sponsor Common Stock, a duly-executed copy of any lock-up or similar agreement in the form to be agreed upon by and between the Company (or its successor) and the investors in the PIPE Closing.

 

Section 1.9. Lender Support Agreements. To the extent requested by the Sponsors, each Lender, on behalf of itself, agrees that it will deliver, substantially simultaneously with the closing of the Business Combination, with respect to its allocation of Sponsor Common Stock, a duly-executed copy of any lender support or similar agreement in the form to be agreed upon by the Sponsors, which may provide that the Lender shall, at any meeting of the stockholders of the Company (or its successor), however called, or at any adjournment thereof, or in any other circumstance in which the vote, consent or other approval of the stockholders of the Company (or its successor) is sought, unconditionally and irrevocably agree that such Lender shall (i) appear at each such meeting or otherwise cause all of its shares of the Sponsor Common Stock (or other security in the Company’s successor) to be counted as present thereat (to the extent entitled to vote thereto) for purposes of calculating a quorum and (ii) vote (or cause to be voted), or execute and deliver a written consent (or cause a written consent to be executed and delivered) covering, all of its shares of Common Stock (to the extent entitled to vote thereto) in favor of those proposals of the Company (or successor) for which the Board of Directors of the Company (or its successor) suggests stockholder approval. Each Lender hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. Notwithstanding the foregoing, such obligation shall expire or terminate at the end of the later of any applicable lock-up period and any forfeiture milestone period as contemplated by Section 1.3(b) above.

 

Section 1.10. Further Assurances. Each Sponsor and each Lender shall take, or cause to be taken, all such further actions and do, or cause to be done, all things reasonably necessary (including under applicable Laws and those agreements entered in to in relation to the Business Combination) to effect the actions required to consummate the transactions contemplated by this Sponsor Agreement and Notes, in each case, on the terms and subject to the conditions set forth therein and herein, as applicable.

 

Section 1.11. No Inconsistent Agreement. Each Sponsor hereby represents and covenants that such Sponsor has not entered into, and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such Sponsor’s obligations hereunder.

 

Section 1.12. No Challenges. Each Sponsor agrees not to voluntarily commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against the Company (or its successor) or any of its respective successors, directors, officers or affiliates, (a) challenging the validity of, or seeking to enjoin the operation of, any provision of this Sponsor Agreement, the Promissory Notes, the Escrow Agreement, the Insider Letter Agreement, or any of the documentation relating to the Business Combination, or (b) alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation or entry into any of the foregoing. Notwithstanding the foregoing, nothing herein shall be deemed to prohibit such Sponsor from enforcing such Sponsor’s rights under this Sponsor Agreement and the other agreements entered into by such Sponsor in connection herewith.

 

 

 

 

Article II

REPRESENTATIONS AND WARRANTIES

 

Section 2.1. Representations and Warranties of the Sponsors. Each Sponsor represents and warrants as of the date hereof to each Lender (solely with respect to itself, himself or herself and not with respect to any other Sponsor) as follows:

 

(a) Organization; Due Authorization. Such Sponsor is duly organized, validly existing and in good standing under the Laws of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Sponsor Agreement and the consummation of the transactions contemplated hereby are within such Sponsor’s corporate, limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such Sponsor. If such Sponsor is an individual, such Sponsor has full legal capacity, right and authority to execute and deliver this Sponsor Agreement and to perform his or her obligations hereunder. This Sponsor Agreement has been duly executed and delivered by such Sponsor and, assuming due authorization, execution and delivery by the other parties to this Sponsor Agreement, this Sponsor Agreement constitutes a legally valid and binding obligation of such Sponsor, enforceable against such Sponsor in accordance with the terms hereof (except as enforceability may be limited by bankruptcy Laws, other similar Laws affecting creditors’ rights and general principles of equity affecting the availability of specific performance and other equitable remedies). If this Sponsor Agreement is being executed in a representative or fiduciary capacity, the person signing this Sponsor Agreement has full power and authority to enter into this Sponsor Agreement on behalf of the applicable Sponsor.

 

(b) Ownership. Such Sponsor is the beneficial owner (as defined in the Securities Act) of, and has good title to, all of such Sponsor’s shares of Sponsor Common Stock, and there exist no liens or any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such shares of Sponsor Common Stock) affecting any such shares of Sponsor Common Stock, other than liens, limitations or restrictions (a) pursuant to (i) this Sponsor Agreement, (ii) the governing documents of the Company, (iii) the Escrow Agreement, (iv) the Insider Letter Agreement, or (v) any applicable securities Laws or (b) that would not, individually or in the aggregate, reasonably be expected to prevent, delay or impair the ability of such Sponsor to perform its obligations under this Sponsor Agreement or the consummation of the transactions contemplated by this Sponsor Agreement or the Notes. None of such Sponsor’s shares of Common Stock are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of such shares of Common Stock, except as provided hereunder and under the applicable insider letter as descried in Section 4.4 of the Escrow Agreement.

 

(c) No Conflicts. The execution and delivery of this Sponsor Agreement by such Sponsor does not, and the performance by such Sponsor of its obligations hereunder will not, (i) conflict with or result in a violation of the organizational documents of such Sponsor or (ii) require any consent or approval that has not been given or other action that has not been taken by any Person (including under any contract binding upon such Sponsor or such Sponsor’s shares of Common Stock), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such Sponsor of its obligations under this Sponsor Agreement.

 

 

 

 

(d) Litigation. There are no Actions pending against such Sponsor, or to the knowledge of such Sponsor threatened against such Sponsor, before (or, in the case of threatened Actions, that would be before) any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such Sponsor of its, his or her obligations under this Sponsor Agreement.

 

(e) Brokerage Fees. No broker, finder, investment banker or other Person is entitled to any brokerage fee, finders’ fee or other commission in connection with the transactions contemplated by Loans

.

(f) Acknowledgment. Such Sponsor understands and acknowledges that each Lender entering into the Loans in reliance upon such Sponsor’s execution and delivery of this Sponsor Agreement.

 

Article III

MISCELLANEOUS

 

Section 3.1. Termination. Unless earlier terminated by the written agreement of the parties hereto, this Sponsor Agreement and all of its provisions shall terminate and be of no further force or effect upon the later of (a) the termination of each of the Notes, and (b) the PIPE Closing. Upon such termination of this Sponsor Agreement, all obligations of the parties under this Sponsor Agreement will terminate, without any liability or other obligation on the part of any party hereto to any Person in respect hereof or the transactions contemplated hereby, and no party hereto shall have any claim against another (and no Person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; provided, however, that the termination of this Sponsor Agreement shall not relieve any party hereto from liability arising in respect of any breach of this Sponsor Agreement prior to such termination. This ARTICLE III shall survive the termination of this Support Agreement.

 

Section 3.2. Governing Law. This Sponsor Agreement, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Sponsor Agreement or the negotiation, execution or performance of this Sponsor Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Sponsor Agreement) will be governed by and construed in accordance with the internal Laws of the State of Delaware applicable to agreements executed and performed entirely within such State.

 

Section 3.3. CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL.

 

(a) ANY PROCEEDING OR ACTION BASED UPON, ARISING OUT OF OR RELATED TO THIS SPONSOR AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY MUST BE BROUGHT IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE (OR, ONLY TO THE EXTENT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE OR, IF IT HAS OR CAN ACQUIRE JURISDICTION, IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE), AND EACH OF THE PARTIES IRREVOCABLY AND UNCONDITIONALLY (I) CONSENTS AND SUBMITS TO THE EXCLUSIVE JURISDICTION OF EACH SUCH COURT IN ANY SUCH PROCEEDING OR ACTION, (II) WAIVES ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE TO PERSONAL JURISDICTION, VENUE OR TO CONVENIENCE OF FORUM, (III) AGREES THAT ALL CLAIMS IN RESPECT OF SUCH PROCEEDING OR ACTION SHALL BE HEARD AND DETERMINED ONLY IN ANY SUCH COURT AND (IV) AGREES NOT TO BRING ANY PROCEEDING OR ACTION ARISING OUT OF OR RELATING TO THIS SUPPORT AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IN ANY OTHER COURT. SERVICE OF PROCESS WITH RESPECT THERETO MAY BE MADE UPON ANY PARTY TO THIS SPONSOR AGREEMENT BY MAILING A COPY THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO SUCH PARTY AT ITS ADDRESS AS PROVIDED IN SECTION 3.8, WITHOUT LIMITING THE RIGHT OF A PARTY TO SERVE PROCESS IN ANY OTHER MATTER PERMITTED BY APPLICABLE LAWS.

 

 

 

 

(b) WAIVER OF TRIAL BY JURY. EACH PARTY HERETO HEREBY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SPONSOR AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS SPONSOR AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SPONSOR AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS SPONSOR AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 3.3.

 

Section 3.4. Assignment. This Sponsor Agreement and all of the provisions hereof will be binding upon and inure to the benefit of the parties hereto and their respective heirs, successors and permitted assigns. Neither this Sponsor Agreement nor any of the rights, interests or obligations hereunder will be assigned (including by operation of law) without the prior written consent of each of the parties hereto.

 

Section 3.5. Specific Performance. The parties hereto agree that irreparable damage may occur in the event that any of the provisions of this Sponsor Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to seek an injunction or injunctions to prevent breaches of this Sponsor Agreement and to enforce specifically the terms and provisions of this Sponsor Agreement, this being in addition to any other remedy to which such party is entitled at law or in equity. In the event that any Action shall be brought in equity to enforce the provisions of this Sponsor Agreement, no party hereto shall allege, and each party hereto hereby waives the defense, that there is an adequate remedy at law, and each party hereto agrees to waive any requirement for the securing or posting of any bond in connection therewith.

 

 

 

 

Section 3.6. Amendment. This Sponsor Agreement may not be amended, changed, supplemented, waived or otherwise modified, except upon the execution and delivery of a written agreement executed by each of the Sponsors and Lenders.

 

Section 3.7. Severability. If any provision of this Sponsor Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Sponsor Agreement will remain in full force and effect. Any provision of this Sponsor Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

Section 3.8. Notices. All notices and other communications among the parties hereto shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid, (c) when delivered by FedEx or other nationally recognized overnight delivery service or (d) when e-mailed during normal business hours of the recipient (and otherwise as of the immediately following Business Day), addressed as follows:

 

If to the Gardiner Sponsor:

 

Contact: Marc F. Pelletier, 3107 Warrington Rd, Shaker Heights, OH 44120

 

If to the Chardan Sponsor:

 

Contact: Jonas Grossman, 17 State Street, 21st Floor, New York, NY 10004

 

If to CCMAUS:

 

Contact: Mohendra Moodley, 8 St Giles Avenue, Greenwich, Sydney, NSW, 2065

 

If to a Lender:

 

To the address set forth opposite such Lenders name in Appendix [I] hereto.

 

Section 3.9. Counterparts. This Sponsor Agreement may be executed in two or more counterparts (any of which may be delivered by electronic transmission), each of which shall constitute an original, and all of which taken together shall constitute one and the same instrument.

 

 

 

 

Section 3.10. Entire Agreement. This Sponsor Agreement and the agreements referenced herein constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by or among the parties hereto to the extent they relate in any way to the subject matter hereof.

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK]

 

IN WITNESS WHEREOF, the Sponsors and the Lenders have each caused this Sponsor Agreement to be duly executed as of the date first written above.

 

  GARDINER HEALTHCARE HOLDINGS, LLC
   
  By: Gardiner Founder, LLC,
  its Managing Member
   
  By: /s/ Marc F. Pelletier
  Name: Marc F. Pelletier
  Title: Manager
   
  CHARDAN GARDINER LLC
   
  By: /s/ Jonas Grossman
  Name: Jonas Grossman
  Title: Managing Member
   
  CCMAUS PTY LTD
   
  By: /s/ Mohendra Moodley
  Name: Mohendra Moodley
  Title: Director

 

[Signature Page to Sponsor Support Agreement]

 

 

 

 

[Add signature pages for the Lenders]

 

[Add Appendix A to Sponsor Support Agreement]

 

 

 

EX-101.SCH 5 tmb-20230323.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 tmb-20230323_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 tmb-20230323_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member] Shares of common stock, par value $0.0001 per share, included as part of the units [Member] Redeemable warrants included as part of the units [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Redeemable warrants included as part of the units Shares of common stock, par value $0.0001 per share, included as part of the units Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant EX-101.PRE 8 tmb-20230323_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 23, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 23, 2023
Entity File Number 001-41185
Entity Registrant Name GARDINER HEALTHCARE ACQUISITIONS CORP.
Entity Central Index Key 0001858912
Entity Tax Identification Number 86-2899992
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3107 Warrington Road
Entity Address, City or Town Shaker Heights
Entity Address, State or Province OH
Entity Address, Postal Zip Code 44120
City Area Code 216
Local Phone Number 633-6708
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant
Trading Symbol GDNRU
Security Exchange Name NASDAQ
Shares of common stock, par value $0.0001 per share, included as part of the units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Shares of common stock, par value $0.0001 per share, included as part of the units
Trading Symbol GDNR
Security Exchange Name NASDAQ
Redeemable warrants included as part of the units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants included as part of the units
Trading Symbol GDNRW
Security Exchange Name NASDAQ
XML 10 tm2310865d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001858912 2023-03-23 2023-03-23 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-03-23 2023-03-23 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-03-23 2023-03-23 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-03-23 2023-03-23 iso4217:USD shares iso4217:USD shares 0001858912 false 8-K 2023-03-23 GARDINER HEALTHCARE ACQUISITIONS CORP. DE 001-41185 86-2899992 3107 Warrington Road Shaker Heights OH 44120 216 633-6708 false false false false Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant GDNRU NASDAQ Shares of common stock, par value $0.0001 per share, included as part of the units GDNR NASDAQ Redeemable warrants included as part of the units GDNRW NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gardinerhealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2310865d1_8k.htm tm2310865d1_ex10-1.htm tm2310865d1_ex10-2.htm tm2310865d1_ex10-3.htm tmb-20230323.xsd tmb-20230323_def.xml tmb-20230323_lab.xml tmb-20230323_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2310865d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "tmb-20230323_def.xml" ] }, "inline": { "local": [ "tm2310865d1_8k.htm" ] }, "labelLink": { "local": [ "tmb-20230323_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230323_pre.xml" ] }, "schema": { "local": [ "tmb-20230323.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 3, "memberStandard": 0, "nsprefix": "tmb", "nsuri": "http://gardinerhealthcare.com/20230323", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2310865d1_8k.htm", "contextRef": "From2023-03-23to2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://gardinerhealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2310865d1_8k.htm", "contextRef": "From2023-03-23to2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "tmb_RedeemableWarrantsIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants included as part of the units", "label": "Redeemable warrants included as part of the units [Member]" } } }, "localname": "RedeemableWarrantsIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230323", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock, par value $0.0001 per share, included as part of the units", "label": "Shares of common stock, par value $0.0001 per share, included as part of the units [Member]" } } }, "localname": "SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230323", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant", "label": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember", "nsuri": "http://gardinerhealthcare.com/20230323", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001104659-23-038409-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-038409-xbrl.zip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෺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end